2Q 2025 Financial Results Nasdaq: NEO 1 July 29, 2025 Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securiti ...

FISCAL Q3 2025 Earnings Conference Call July 29, 2025 FORWARD-LOOKING AND CAUTIONARY STATEMENTS/NON-GAAP FINANCIAL INFORMATION Johnson Controls International plc cautionary statement regarding forward-looking statements Johnson Controls International plc has made statements in this communication that are forward-looking and therefore are subject to risks and uncertainties. All statements in this document other than statements of historical fact are, or could be, "forward-looking statements" within the meani ...

Financial Performance - UPS's revenue for 2Q25 was $21221 million, a decrease of 27% year-over-year compared to $21818 million in 2Q24[22] - Non-GAAP adjusted operating profit was $1876 million, down 91% from $2064 million in the same period last year[22] - The non-GAAP adjusted operating margin was 88%, a decrease of 70 basis points compared to 95% in 2Q24[22] - Non-GAAP adjusted diluted EPS was $155, a decrease of 134% compared to $179 in 2Q24[22] Segment Performance - U S Domestic revenue decreased by 08% year-over-year to $141 billion[37, 40] - U S Domestic non-GAAP adjusted operating profit was $982 million, a decrease of 14% year-over-year[40] - International revenue increased by 26% year-over-year to $45 billion[43] - International non-GAAP adjusted operating profit was $682 million, a decrease of 172% year-over-year[43] - Supply Chain Solutions revenue decreased by 183% year-over-year to $27 billion, primarily due to the divestiture of Coyote[44] Strategic Actions and Outlook - The company expects approximately $35 billion in cost reductions in 2025[27, 48] - Capital expenditures are projected to be approximately $35 billion in 2025[51] - Dividend payments are estimated to be approximately $55 billion in 2025, subject to Board approval[51]

Company Overview - PJT Partners is presented as a premier, global, advisory-focused investment bank[11] with a market capitalization of approximately $72 billion[14] - The company has grown to 129 partners globally[14] with an average partner experience of over 25 years[14], and employs 1,155 people across 15 offices in over 60 countries[14] - The firm serves over 400 clients[14] and has achieved approximately $15 billion in LTM 2Q25 revenues[14] Growth and Performance - Since 2015, the company has experienced significant growth, including a 180% increase in total partner count[27] and a 227% increase in total headcount[27] - Revenue has increased by 278% from $406 million in 2015 to $1535 million in LTM 2Q25[27] - Adjusted EPS has increased by 250% from $155 in 2016 to $542 in LTM 2Q25[27] - Adjusted Pretax Income has increased by 601% from $42 million in 2015 to $294 million in LTM 2Q25[27] Financial Highlights (2Q25) - Revenue for the second quarter of 2025 was $407 million, a 13% increase[68] - GAAP Pretax Income was $76 million, a 19% increase[68], while Adjusted Pretax Income was $80 million, a 22% increase[68] - GAAP Diluted EPS was $121, a 14% increase[68], and Adjusted EPS was $154, a 29% increase[68] Financial Highlights (First Half 2025) - Revenue for the first half of 2025 was $731 million, a 6% increase[68] - GAAP Pretax Income was $129 million, a 9% increase[68], while Adjusted Pretax Income was $136 million, a 13% increase[68] - GAAP Diluted EPS was $321, a 40% increase[68], and Adjusted EPS was $259, a 19% increase[68] Financial Highlights (LTM 2Q25) - Revenue for the last twelve months ending 2Q25 was $1535 million, an 18% increase[68] - GAAP Pretax Income was $281 million, a 32% increase[68], while Adjusted Pretax Income was $294 million, a 35% increase[68] - GAAP Diluted EPS was $582, a 52% increase[68], and Adjusted EPS was $542, a 38% increase[68] Capital Management - The company prioritizes investing in its business, offsetting dilution, and maintaining a dividend[70] - The company has a disciplined approach to expense management and maintains a strong cash position[70] - Approximately 40% employee ownership aligns senior management awards with shareholder value creation[70] - The company has repurchased shares, spending $438 million on share repurchases in LTM 2Q25[74]

Financial Performance - Revenue for 2Q 2025 was $282 million[6], a decrease of $116 million or 29% compared to 2Q 2024[6, 10] - Gross margin for 2Q 2025 was 23.7%[6, 15], an increase of 360 bps compared to 2Q 2024[6, 15] - Adjusted EBITDA for 2Q 2025 was -$8 million[6, 26], an improvement of $28 million compared to 2Q 2024[6, 26] - G&A and Tech Expense for 2Q 2025 was $37 million[6, 23], a decrease of $9 million or 19% compared to 2Q 2024[6, 23] Customer & Order Metrics - Orders delivered (LTM) were 5.7 million[33], a decrease of 2.9 million or 33.8% compared to 2Q 2024[30, 31] - Average order value was $219[33], an increase of 7.2% compared to 2Q 2024[33] - Active customers (LTM) were 4.4 million[36], a decrease of 1.9 million or 30% compared to 2Q 2024[36] - Order frequency was 1.32[36], a decrease of 5.4% compared to 2Q 2024[36] Expense Management - The company is targeting a $150 million annual G&A and Tech Expense run rate[23, 40] - Sales & Marketing Expense was $38 million or 13.5% of revenue[17, 18], a decrease of $28 million or 320 bps compared to 2Q 2024[18]

ARCALYST Performance and Market - ARCALYST has generated over $1 billion in revenue since its launch[7] - Expected 2025 ARCALYST revenue is projected to be between $625 million and $640 million[7, 51] - ARCALYST has achieved approximately 15% penetration into the target population of recurrent pericarditis patients as of Q2 2025[7, 23, 29] - Approximately 80% of ARCALYST prescriptions are for patients with ≥3rd recurrence[23] - Approximately 20% of ARCALYST prescriptions are for patients in their 1st recurrence[23] - Payer approval for ARCALYST exceeds 90% of completed cases[28] - Approximately 45% of patients restarted ARCALYST therapy following initial discontinuation within ~8 weeks[37, 40] - The average total duration of ARCALYST therapy is approximately 30 months[28, 40] Financial Position - Kiniksa reported Q2 2025 cash reserves of approximately $308 million[8] - Kiniksa's operating plan is expected to remain cash flow positive on an annual basis[7, 78] - ARCALYST net sales for Q2 2025 were $156.8 million, compared to $103.4 million in Q2 2024[77] KPL-387 Development - A Phase 2/3 trial for KPL-387 in recurrent pericarditis has been initiated, with Phase 2 dose-focusing data expected in the second half of 2026[8]

Q2 2025 Financial Performance - Total property revenue increased by 1.2% year-over-year to $2.527 billion, with a 1.9% increase on an FX-neutral basis[5] - Total revenue increased by 3.2% year-over-year to $2.627 billion, with a 3.9% increase on an FX-neutral basis[5] - Net income attributable to AMT common stockholders decreased by 59.3% to $367 million, with a per diluted share of $0.78[5] - Adjusted EBITDA increased by 1.8% year-over-year to $1.752 billion, with a 2.6% increase on an FX-neutral basis; Adjusted EBITDA margin was 66.7%[5] - AFFO attributable to AMT common stockholders decreased by 6.7% to $1.218 billion, with a per diluted share of $2.60; As adjusted, AFFO increased by 2.6% to $1.218 billion, with a per diluted share of $2.60[5] 2025 Outlook Revisions - The company raised the 2025 property revenue outlook by $165 million to $10.21 billion, representing ~3% year-over-year growth[20] - The company raised the 2025 Adjusted EBITDA outlook by $120 million to $7.04 billion, representing >3% year-over-year growth[27] - The company raised the 2025 Attributable AFFO outlook by $55 million to $4.95 billion, or $10.56 per share, representing ~6% year-over-year per share growth (as adjusted)[31] Capital Allocation - The company plans to deploy $1.5 billion in discretionary capital projects, with approximately 40% allocated to U.S. Data Centers, 25% to U.S. & Canada, 15% to Europe, and 20% to Emerging Markets[36] - The company targets a common dividend declaration of approximately $3.2 billion[39]

Second Quarter 2025 Financial Results & Business Update July 29, 2025 Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc's (the "Company") expectations with respect to its current and future financial, commercial and operating performance, business plans o ...

Financial Performance - The company reported total revenue of $3.9 billion, a 2% decrease compared to the prior year, attributed to a slow outdoor buying season and tariff-related shipment disruptions[6, 7] - Adjusted gross margin was 27.5%, down from the prior year, impacted by a 3-point gross impact from tariffs and lower volume, partially offset by supply chain efficiencies and price increases[6, 7] - Adjusted EPS was $1.08, inclusive of a tax rate benefit[6, 7] - Net cash from operating activities was $214 million, and free cash flow was $135 million[7] Segment Performance - Tools & Outdoor segment revenue decreased by 2% to $3.461 billion, with an adjusted segment margin of 8.0%, down year-over-year due to tariffs, lower volume, and growth investments[9] - Engineered Fastening segment revenue decreased by 2% to $484 million, with an adjusted segment margin of 10.8%, down year-over-year due to lower volume in higher margin automotive[10] Transformation and Cost Savings - The company's transformation program has achieved $150 million in quarter-to-date pre-tax run-rate cost savings and $1.8 billion program-to-date[6, 12] - The company is targeting completion of the transformation in 2025, focusing on material productivity, operational excellence, complexity reduction, and footprint rationalization[12] Tariffs and Mitigation - The company estimates an annualized gross impact of $800 million from tariffs, with a net impact of $0.65 EPS for fiscal year 2025[16] - Mitigation strategies include price increases, supply chain adjustments, and engagement with the U.S administration[15, 17] 2025 Planning Assumptions - The company's base planning scenario for 2025 includes GAAP EPS of $3.45 (+/- $0.10) and adjusted EPS of approximately $4.65[7] - The company is targeting free cash flow to approximate $600 million in 2025[7, 18]

Financial Performance - Net revenues reached €743 billion, a decrease of 13% year-over-year [11, 15, 19, 37] - Adjusted Operating Income (AOI) was €05 billion, with an AOI margin of 07%, a decrease of 930 bps [11, 15, 22, 37] - Industrial Free Cash Flow (FCF) was negative €30 billion, compared to negative €04 billion in the previous year [11, 15, 28, 37] - Adjusted Diluted EPS was €018, a decrease of 92% [15, 37] Regional Performance - North America (NA) reported net revenues of €282 billion and an AOI loss of €10 billion, with an AOI margin of negative 34% [34] - Enlarged Europe reported net revenues of €292 billion and an AOI of €90 million, with an AOI margin of 00% [34] - South America reported net revenues of €78 billion and an AOI of €12 billion, with an AOI margin of 153% [34] - Middle East & Africa reported net revenues of €49 billion and an AOI of €08 billion, with an AOI margin of 155% [34] Strategic Initiatives and Outlook - The company estimates a net tariff impact of approximately €15 billion for 2025 [11, 40] - H2 2025 guidance indicates sequential improvement in net revenues and industrial FCF compared to H1 2025, with a low-single digit AOI margin [11, 42] - The company is adapting to evolving tariffs and focusing on mitigation strategies [39, 41]